公开(公告)号：US20120001875A1

公开(公告)日：2012-01-05

申请号：US12885151

申请日：2010-09-17

Applicant: Ren Li ,  Te-Won Lee ,  Hui-ya L. Nelson ,  Samir K. Gupta

Inventor： Ren Li ,  Te-Won Lee ,  Hui-ya L. Nelson ,  Samir K. Gupta

IPC: G06F3/043

CPC classification number: G06F3/011 ,  G01S7/5273 ,  G01S15/325 ,  G01S15/50 ,  G01S15/876 ,  G06F3/017

Abstract: The embodiments provide systems and methods for touchless sensing and gesture recognition using continuous wave sound signals. Continuous wave sound, such as ultrasound, emitted by a transmitter may reflect from an object, and be received by one or more sound receivers. Sound signals may be temporally encoded. Received sound signals may be processed to determine a channel impulse response or calculate time of flight. Determined channel impulse responses may be processed to extract recognizable features or angles. Extracted features may be compared to a database of features to identify a user input gesture associated with the matched feature. Angles of channel impulse response curves may be associated with an input gesture. Time of flight values from each receiver may be used to determine coordinates of the reflecting object. Embodiments may be implemented as part of a graphical user interface. Embodiments may be used to determine a location of an emitter.

Abstract translation: 这些实施例提供了使用连续波声信号的无接触感测和手势识别的系统和方法。 由发射器发射的连续波声，如超声波，可能会从物体反射，并由一个或多个声音接收器接收。 声音信号可能是时间编码的。 可以处理接收的声音信号以确定信道脉冲响应或计算飞行时间。 可以处理确定的信道脉冲响应以提取可识别的特征或角度。 提取的特征可以与特征数据库进行比较，以识别与匹配特征相关联的用户输入手势。 信道脉冲响应曲线的角度可以与输入手势相关联。 可以使用来自每个接收机的飞行时间值来确定反射对象的坐标。 实施例可以被实现为图形用户界面的一部分。 实施例可以用于确定发射器的位置。

公开(公告)号：US20110293103A1

公开(公告)日：2011-12-01

申请号：US13149714

申请日：2011-05-31

Applicant: Hyun Jin Park ,  Erik Visser ,  Jongwon Shin ,  Kwokleung Chan ,  Samir K. Gupta ,  Andre Gustavo P. Schevciw ,  Ren Li ,  Jeremy P. Toman

Inventor： Hyun Jin Park ,  Erik Visser ,  Jongwon Shin ,  Kwokleung Chan ,  Samir K. Gupta ,  Andre Gustavo P. Schevciw ,  Ren Li ,  Jeremy P. Toman

IPC: H03G3/20

CPC classification number: G10K11/1782 ,  G10K11/178 ,  G10L21/0208 ,  G10L2021/02082 ,  G10L2021/02165 ,  H04R2460/01

Abstract: Methods and apparatus for generating an anti-noise signal and equalizing a reproduced audio signal (e.g., a far-end telephone signal) are described, wherein the generating and the equalizing are both based on information from an acoustic error signal.

Abstract translation: 描述了用于产生抗噪声信号和均衡再现的音频信号（例如，远端电话信号）的方法和装置，其中生成和均衡均基于来自声学误差信号的信息。

公开(公告)号：US08119602B2

公开(公告)日：2012-02-21

申请号：US11443793

申请日：2006-05-31

Applicant: Jenny Zhang ,  Samir K. Gupta

Inventor： Jenny Zhang ,  Samir K. Gupta

IPC: A61K38/05

CPC classification number: C07K5/0827 ,  A23G3/36 ,  A23L33/10 ,  A23L33/17 ,  A61K31/40 ,  A61K31/4709 ,  A61K38/05 ,  A61K38/06 ,  A61K38/08 ,  A61K38/212 ,  A61K45/06 ,  C07K5/0205 ,  C07K5/0812 ,  A61K2300/00

Abstract: Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.

Abstract translation: 提供了治疗，预防或改善受试者中一种或多种丙型肝炎症状的方法，其包括与食物组合施用至少一种HCV蛋白酶抑制剂的步骤。 还提供了提高HCV蛋白酶抑制剂的生物利用度的方法和增加受试者中HCV蛋白酶抑制剂血清水平的方法。 所有方法包括至少一种HCV蛋白酶抑制剂与食物组合，所述至少一种HCV蛋白酶抑制剂选自本文所述的式I-XXVI化合物。 与没有食物的给药相比，本发明化合物与食物组合施用提供了改善的生物利用度和化合物的峰值血清水平。

公开(公告)号：US07405223B2

公开(公告)日：2008-07-29

申请号：US09760588

申请日：2001-01-16

Applicant: Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

Inventor： Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

IPC: A61K31/44

CPC classification number: A61K31/4545 ,  Y10S514/96

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract translation: 治疗和/或预防皮肤或上，下呼吸道通路的过敏和炎症状况的方法，例如， 季节性过敏性鼻炎，常年性过敏性鼻炎或慢性感染性荨麻疹，在12岁以上的人中，通过施用一定量的去氯雷他定，例如， 2x2.5mg或5mg /天，足以产生在约2.90ng / mL至约4.54ng / mL范围内的地氯雷他定的几何平均稳态最大血浆浓度，或算术平均稳态最大血浆浓度 的脱氯雷他定在约3.2ng / mL至约5.0ng / mL的范围内。

公开(公告)号：US6048857A

公开(公告)日：2000-04-11

申请号：US9678

申请日：1998-01-20

Applicant: Everett H. Ellinwood, Jr. ,  Samir K. Gupta

Inventor： Everett H. Ellinwood, Jr. ,  Samir K. Gupta

IPC: A61K31/55

CPC classification number: A61K31/137 ,  A61K31/496 ,  A61K31/5513

Abstract: A method of therapeutically administering certain medicaments in order to maximize the desired effects and minimize the unwanted metabolite effects on the human body, including the central nervous system, in order to maximize therapeutic effects, such as anti-anxiety, anticonvulsant and hypnotic effects, and minimize unwanted side effects, such as ataxic and incoordination effects, of the medicament. Also, a method of inhalation administration or skin administration of certain medicaments in order to decrease metabolism of the medicaments to unwanted metabolites.

Abstract translation: 治疗性施用某些药物的方法是为了最大化期望的效果并最小化对包括中枢神经系统在内的人体的不希望的代谢物作用，以最大限度地发挥治疗效果，例如抗焦虑，抗惊厥和催眠作用，以及 最小化药物的不希望的副作用，如共济失调和不协调的作用。 此外，吸入给药或某些药物的皮肤给药方法是为了将药物的代谢降低为不需要的代谢物。

公开(公告)号：US20080262018A1

公开(公告)日：2008-10-23

申请号：US12155250

申请日：2008-05-30

Applicant: Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

Inventor： Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

IPC: A61K31/4545 ,  A61P37/08

CPC classification number: A61K31/4545 ,  Y10S514/96

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

公开(公告)号：US5504086A

公开(公告)日：1996-04-02

申请号：US321246

申请日：1994-10-11

Applicant: Everett H. Ellinwood, Jr. ,  Samir K. Gupta

Inventor： Everett H. Ellinwood, Jr. ,  Samir K. Gupta

IPC: A61K31/137 ,  A61K31/222 ,  A61K31/496 ,  A61K31/5513 ,  A61K31/495 ,  A61K31/50

CPC classification number: A61K31/496 ,  A61K31/137 ,  A61K31/222 ,  A61K31/5513

Abstract: A method of therapeutically administering certain BZ.sub.1 specific trifluorobenzodiazepines in order to maximize the BZ.sub.1 effects and minimize the BZ.sub.2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug. Also, a method of sublingual administration of trifluorobenzodiazepines and certain other compounds, such as propoxyphene and nefazodone, in order to decrease unwanted metabolites.

Abstract translation: 一种治疗性施用某些BZ1特异性三氟苯并二氮杂卓的方法，以使BZ1效应最大化并使BZ2对人中枢神经系统的作用最小化，以最大化抗焦虑，抗惊厥和催眠作用，并使药物的共济失调和不协调作用最小化 。 另外，一种舌下给予三氟苯并二氮杂类物质和某些其它化合物如丙氧芬和奈法唑酮的方法，以减少不必要的代谢物。

公开(公告)号：US07902208B2

公开(公告)日：2011-03-08

申请号：US12155250

申请日：2008-05-30

Applicant: Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

Inventor： Melton B. Affrime ,  Christopher R. Banfield ,  Samir K. Gupta ,  Desmond Padhi

IPC: A61K31/44

CPC classification number: A61K31/4545 ,  Y10S514/96

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract translation: 治疗和/或预防皮肤或上，下呼吸道通路的过敏和炎症状况的方法，例如， 季节性过敏性鼻炎，常年性过敏性鼻炎或慢性感染性荨麻疹，在12岁以上的人中，通过施用一定量的去氯雷他定，例如， 2×2.5mg或5mg /天，足以产生在约2.90ng / mL至约4.54ng / mL范围内的地氯雷他定的几何平均稳态最大血浆浓度，或算术平均稳态最大血浆浓度 的脱氯雷他定在约3.2ng / mL至约5.0ng / mL的范围内。

公开(公告)号：US20100291034A1

公开(公告)日：2010-11-18

申请号：US12839097

申请日：2010-07-19

Applicant: Robert O RALSTON, II ,  Julie M. Strizki ,  Jaromir Vlach ,  Samir K. Gupta ,  Edward M. O'Mara, JR. ,  Anima Ghosal ,  Michelle A. Treitel ,  James F. McLeod ,  Ronald E. White

Inventor： Robert O RALSTON, II ,  Julie M. Strizki ,  Jaromir Vlach ,  Samir K. Gupta ,  Edward M. O'Mara, JR. ,  Anima Ghosal ,  Michelle A. Treitel ,  James F. McLeod ,  Ronald E. White

IPC: A61K38/21 ,  A61K38/05 ,  A61P31/14

CPC classification number: A61K31/496 ,  A61K31/16 ,  A61K31/192 ,  A61K31/395 ,  A61K31/40 ,  A61K31/403 ,  A61K31/427 ,  A61K31/4965 ,  A61K38/07 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.

Abstract translation: 公开了药物，药物组合物，药物试剂盒和基于组合的方法，所述组合包括，单独或一起：（a）CYP3A4抑制剂; 和（b）HCV蛋白酶抑制剂; 用于同时或连续给药以治疗感染HCV的人类受试者。

公开(公告)号：US06606382B2

公开(公告)日：2003-08-12

申请号：US09491933

申请日：2000-01-27

Applicant: Samir K. Gupta

Inventor： Samir K. Gupta

IPC: H04M100

CPC classification number: H04M9/082

Abstract: A system and method for canceling an echo signal. An input waveform is provided to an acoustic processor, and a determination is made whether the input waveform includes information representative of an echo signal. If the input waveform includes information representative of an echo signal, an output waveform is formed by attenuating a residual waveform with the acoustic processor. The residual waveform is attenuated by an attenuation factor that gradually changes from an initial attenuation value to a final attenuation value during the attenuation step. A system and method for adjusting an acoustic signal from a muted state to an unmuted state by varying an attenuation factor applied to an acoustic signal by an acoustic processor. The acoustic signal is provided to an acoustic processor. An output waveform is formed from the acoustic processor by adjusting the attenuation factor from a muted state to a first attenuation value associated with the non-muted state. After the attenuation factor is adjusted to the first attenuation value, the output waveform is formed by gradually changing the attenuation factor from the first attenuation value to a second attenuation value. The input waveform is attenuated by a smaller amount when the second attenuation value is applied to the acoustic signal than when the first attenuation value is applied to the acoustic signal.

Abstract translation: 一种消除回波信号的系统和方法。 向声学处理器提供输入波形，并且确定输入波形是否包括表示回波信号的信息。 如果输入波形包括表示回波信号的信息，则通过用声处理器衰减残留波形来形成输出波形。 残余波形衰减衰减因子，该衰减因子在衰减步骤期间从初始衰减值逐渐变化到最终衰减值.1。一种用于通过改变应用的衰减因子来调整从静音状态到未静音状态的声信号的系统和方法 通过声学处理器到声学信号。 将声学信号提供给声学处理器。 通过将从静音状态的衰减因子调整到与非静音状态相关联的第一衰减值，从声学处理器形成输出波形。 在将衰减因子调整到第一衰减值之后，通过将衰减因子从第一衰减值逐渐改变为第二衰减值来形成输出波形。 当第二衰减值被施加到声学信号时，输入波形被衰减较少，当第一衰减值被施加到声学信号时。